HELPCybin D/B/A Helus Pharma
$6.24-31% 1Y
$6.24
$3.8752 weeks$14.03
Is the business good?
How good a business is HELP?
Cybin D/B/A Helus Pharma keeps −1627% of every revenue dollar as operating profit, against −77% for the median Biotechnology name.
−1627%
Operating margin · Biotechnology median −77% · fiscal year to FY2025
- Share count, year on year
- +144%
Share count, year on year · shareholders own a smaller slice than a year ago
- R&D as % of revenue
- 662%
R&D as % of revenue
| Year | Operating margin |
|---|---|
| FY2021 | −50873% |
| FY2022 | −26389% |
| FY2023 | −8444% |
| FY2024 | −12636% |
| FY2025 | −1627% |
Details›
- Operating marginfiscal year to FY2025
- −1627%
- Net marginfiscal year to FY2025
- −1365%
- R&D as % of revenue
- 662%
- Revenue, trailing twelve months
- $8.3M
- Net income, trailing twelve months
- −$113M
Margins, capital and share counts from the statements as filed with the SEC; cash conversion is operating cash flow over operating profit after tax.